University of California San Diego Medical Center: Transplantation
Welcome,         Profile    Billing    Logout  
 8 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Durand, Christine
THINKER-NEXT, NCT04075916: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

Active, not recruiting
2
201
US
Epclusa
University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease
06/25
01/26
CPAT-SG, NCT05518487: COVID Protection After Transplant - Sanofi GSK () Study

Active, not recruiting
2
80
US
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University, Sanofi Pasteur, a Sanofi Company
COVID-19, Kidney Transplant
02/24
07/25
Aslam, Saima
CPAT-ISR, NCT05077254: COVID Protection After Transplant-Immunosuppression Reduction

Active, not recruiting
2
400
US
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, mRNA COVID-19 vaccine, BNT162b2 mRNA COVID-19 vaccine, SARS-CoV-2 RNA vaccine, Comirnaty, Moderna COVID-19 Vaccine 2023-2024, Moderna COVID-19 vaccine, SARS-CoV-2 vaccine, Spikevax, SOC IS Regimen, Standard of Care transplant immunosuppression regimen, Immunosuppression (IS), mycophenolate mofetil (MMF) or equivalent, tacrolimus, SOC IS Reduction, Standard of Care (SOC) transplant immunosuppression regimen, Immunosuppression (IS) Reduction
National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University
Kidney Transplant Recipients, Liver Transplant Recipients
02/24
03/25
CPAT-SG, NCT05518487: COVID Protection After Transplant - Sanofi GSK () Study

Active, not recruiting
2
80
US
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University, Sanofi Pasteur, a Sanofi Company
COVID-19, Kidney Transplant
02/24
07/25
diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Recruiting
1/2
50
US, RoW
AP-SA02, Placebo
Armata Pharmaceuticals, Inc., United States Department of Defense
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
12/24
03/25
Esshaki, Yasmeen
CPAT-SG, NCT05518487: COVID Protection After Transplant - Sanofi GSK () Study

Active, not recruiting
2
80
US
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University, Sanofi Pasteur, a Sanofi Company
COVID-19, Kidney Transplant
02/24
07/25

Download Options